Pulmonary Embolism (PE) Therapeutics - Pipeline Assessment and Market Forecasts to 2019

GlobalData, February 2012, Pages: 70

Pulmonary Embolism (PE) Therapeutics - Pipeline Assessment and Market Forecasts to 2019

Summary

GlobalData, the industry analysis specialist, has released its new report, “Pulmonary Embolism (PE) Therapeutics - Pipeline Assessment and Market Forecasts to 2019”. The report is an essential source of information and analysis on the global Pulmonary Embolism Therapeutics market. The report identifies the key trends shaping and driving the global Pulmonary Embolism Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Pulmonary Embolism Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

Scope

The report provides information on the key drivers and challenges of the Pulmonary Embolism Therapeutics market. Its scope includes -
- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Pulmonary Embolism Therapeutics market revenues data from 2005 to 2010, forecast for eight years to 2019.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes.
- Analysis of the current and future competition in the seven key countries Pulmonary Embolism Therapeutics market.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Pulmonary Embolism Therapeutics market.
- Analysis of key recent licensing and partnership agreements in Pulmonary Embolism Therapeutics market

Reasons to buy

The report will enhance your decision making capability. It will allow you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global Pulmonary Embolism Therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Pulmonary Embolism Therapeutics market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What’s the next big thing in the global Pulmonary Embolism Therapeutics market landscape? – Identify, understand and capitalize.

1
1

1.1 List of Tables
1.2 List of Figures
2 Pulmonary Embolism (PE) - Introduction
2.1 Overview
2.2 Epidemiology
2.3 Etiology
2.3.1 Stagnant Blood Flow
2.3.2 Coagulation
2.3.3 Damage to the Vein Walls
2.3.4 Other Risk Factors
2.4 Clinical Presentation/Symptoms
2.5 Diagnosis
2.5.1 Electrocardiography
2.5.2 Chest Radiography
2.5.3 Arterial Blood Gas (ABG) Determination
2.5.4 Computed Tomographic Pulmonary Angiography
2.5.5 Ventilation-Perfusion Scanning
2.5.6 Magnetic Resonance Angiography
2.5.7 Biomarkers (Troponins and Brain Natriuretic Peptide)
2.5.8 Echocardiography (Transthoracic and Transesophageal)
2.6 Pathophysiology
2.7 Treatment
2.7.1 Anticoagulation
2.7.2 Unfractionated Heparin (UFH)
2.7.3 Low Molecular Weight Heparin (LMWH)
2.7.4 Indirect Factor Xa Inhibitors
2.7.5 Thrombolytic agents
2.7.6 Warfarin
2.8 Other Procedures and Devices for Pulmonary Embolism
2.8.1 Pulmonary Embolectomy
2.8.2 Vena Caval Interruption
2.9 GlobalData Pipeline Report Guidance
3 Pulmonary Embolism Therapeutics - Market Characterization
3.1 Overview
3.2 Pulmonary Embolism Therapeutics Market Size (2006-2011) - Global
3.3 Pulmonary Embolism Therapeutics Market Forecast (2011-2019) - Global
3.4 Pulmonary Embolism Therapeutics Market Size (2006-2011) - The US
3.5 Pulmonary Embolism Therapeutics Market Forecast (2011-2019) - The US
3.6 Pulmonary Embolism Therapeutics Market Size (2006-2011) - France
3.7 Pulmonary Embolism Therapeutics Market Forecast (2011-2019) - France
3.8 Pulmonary Embolism Therapeutics Market Size (2006-2011) - Germany
3.9 Pulmonary Embolism Therapeutics Market Forecast (2011-2019) - Germany
3.10 Pulmonary Embolism Therapeutics Market Size (2006-2011) - Italy
3.11 Pulmonary Embolism Therapeutics Market Forecast (2011-2019) - Italy
3.12 Pulmonary Embolism Therapeutics Market Size (2006-2011) - Spain
3.13 Pulmonary Embolism Therapeutics Market Forecast (2011-2019) - Spain
3.14 Pulmonary Embolism Therapeutics Market Size (2006-2011) - The UK
3.15 Pulmonary Embolism Therapeutics Market Forecast (2011-2019) - The UK
3.16 Pulmonary Embolism Therapeutics Market Size (2006-2011) - Japan
3.17 Pulmonary Embolism Therapeutics Market Forecast (2011-2019) - Japan
3.18 Drivers and Barriers for the Pulmonary Embolism Therapeutics Market
3.18.1 Drivers for the Pulmonary Embolism Therapeutics Market
3.18.2 Barriers for the Pulmonary Embolism Therapeutics Market
3.19 Opportunity and Unmet Need
3.20 Key Takeaway
4 Pulmonary Embolism Therapeutics Market - Competitive Assessment
4.1 Overview
4.2 Strategic Competitor Assessment
4.3 Product Profiles of the Major Marketed Products in the Pulmonary Embolism Therapeutics Market - Heparin Class
4.3.1 Enoxaparin (Lovenox or Clexane)
4.3.2 Dalteparin (Fragmin)
4.3.3 Warfarin
4.3.4 Xarelto
4.3.5 Fondaparinux (Arixtra)
4.3.6 Apixaban (Eliquis)
4.4 Key Takeaway
5 Pulmonary Embolism Therapeutics Market - Pipeline Assessment
5.1 Overview
5.1.1 Pulmonary Embolism Therapeutics –Phase III Clinical Pipeline
5.1.2 Pulmonary Embolism Therapeutics – Phase II Clinical Pipeline
5.1.3 Pulmonary Embolism Therapeutics – Regulatory and Phase I Clinical Pipeline
5.1.4 Pulmonary Embolism Therapeutics – Preclinical and Discovery Clinical Pipeline
5.2 Pulmonary Embolism Therapeutics Market - Pipeline Assessment by Mechanism of Action
5.3 Pulmonary Embolism Therapeutics Market - Technology Trends Analytical Framework
5.4 Pulmonary Embolism Therapeutics Market - Pipeline Assessment by Clinical Phase of Development
5.5 Pulmonary Embolism Therapeutics - Promising Drugs under Clinical Development
5.6 Molecule Profile for Promising Drugs under Clinical Development
5.6.1 Edoxaban
5.7 Key Takeaway
6 Pulmonary Embolism Therapeutics - Clinical Trials Mapping
6.1 Clinical Trials by Region/Country
6.2 Clinical Trials by Phase of Clinical Development
6.3 Clinical Trials by Trial Status
6.4 Prominent and Overall Sponsors
6.5 Brief Profiles of Top 10 Companies Participating in Clinical Trials
7 Pulmonary Embolism Therapeutics - Strategic Assessment
7.1 Key Events Impacting the Future Market
7.2 Future Market Competition Scenario
8 Pulmonary Embolism Therapeutics - Future Players
8.1 Introduction
8.1.1 Boehringer Ingelheim GmbH
8.1.2 Bristol-Myers Squibb
8.1.3 Daiichi Sankyo
8.1.4 Pfizer Inc.
8.1.5 Sanofi
9 Pulmonary Embolism Therapeutics Market - Appendix
9.1 Market Definition
9.2 Abbreviations
9.3 Methodology
9.3.1 Coverage
9.3.2 Secondary Research
9.3.3 Forecasting
9.3.4 Primary Research
9.3.5 Expert Panel Validation
9.4 Contact Us
9.5 Disclaimer
9.6 Bibliography

1.1 List of Tables
Table 1: Pulmonary Embolism Therapeutics Market, Global, Revenues ($m), 2006–2011
Table 2: Pulmonary Embolism Therapeutics Market, Global, Market Forecasts ($m), 2011–2019
Table 3: Pulmonary Embolism Therapeutics Market, The US, Revenue ($m), 2006–2011
Table 4: Pulmonary Embolism Therapeutics Market, The US, Market Forecasts ($m), 2011–2019
Table 5: Pulmonary Embolism Therapeutics Market, France, Revenue ($m), 2006–2011
Table 6: Pulmonary Embolism Therapeutics Market, France, Market Forecast ($m), 2011–2019
Table 7: Pulmonary Embolism Therapeutics Market, Germany, Revenue ($m), 2006–2011
Table 8: Pulmonary Embolism Therapeutics Market, Germany, Market Forecast ($m), 2011–2019
Table 9: Pulmonary Embolism Therapeutics Market, Italy, Revenue ($m), 2006–2011
Table 10: Pulmonary Embolism Therapeutics Market, Italy, Market Forecast ($m), 2011–2019
Table 11: Pulmonary Embolism Therapeutics Market, Spain, Revenue ($m), 2006–2011
Table 12: Pulmonary Embolism Therapeutics Market, Spain, Market Forecast ($m), 2011–2019
Table 13: Pulmonary Embolism Therapeutics Market, The UK, Revenue ($m), 2006–2011
Table 14: Pulmonary Embolism Therapeutics Market, The UK, Market Forecast ($m), 2011–2019
Table 15: Pulmonary Embolism Market, Japan, Revenue ($m), 2006–2011
Table 16: Pulmonary Embolism Therapeutics Market, Japan, Market Forecast ($m), 2011–2019
Table 17: Major Marketed Products Comparison in the Pulmonary Embolism Therapeutics Market, 2011
Table 18: Pulmonary Embolism Therapeutics Market – Phase III Clinical Pipeline, 2011
Table 19: Pulmonary Embolism Therapeutics Market – Phase II Clinical Pipeline, 2011
Table 20: Pulmonary Embolism Therapeutics Market – Phase I Clinical Pipeline, 2011
Table 21: Pulmonary Embolism Therapeutics Market – Preclinical Pipeline, 2011
Table 22: Pulmonary Embolism Therapeutics – Most Promising Drugs under Clinical Development, 2011
Table 23: Pulmonary Embolism Therapeutics Market, Global, Clinical Trials, 2011
Table 24: Pulmonary Embolism Therapeutics Market, Global, Clinical Trials by Phase, 2011
Table 25: Pulmonary Embolism Therapeutics Market, Global, Clinical Trials by Status of Development, 2011
Table 26: Pulmonary Embolism Therapeutics Market, Global, Sponsors, 2011
Table 27: Pulmonary Embolism Therapeutics Market, Global, Companies by Phase, 2011

1.2 List of Figures
Figure 1: Pulmonary Embolism Clinical Presentation
Figure 2: Pulmonary Embolism Therapeutics Market, Global, Revenues ($m), 2006–2011
Figure 3: Pulmonary Embolism Therapeutics Market, Global, Market Forecast ($m), 2011–2019
Figure 4: Pulmonary Embolism Therapeutics Market, The US, Revenue ($m), 2006–2011
Figure 5: Pulmonary Embolism Therapeutics Market, The US, Market Forecasts ($m), 2011–2019
Figure 6: Pulmonary Embolism Therapeutics Market, France, Revenue ($m), 2006–2011
Figure 7: Pulmonary Embolism Therapeutics Market, France, Market Forecast ($m), 2011–2019
Figure 8: Pulmonary Embolism Therapeutics Market, Germany, Revenue ($m), 2006–2011
Figure 9: Pulmonary Embolism Therapeutics Market, Germany, Market Forecast ($m), 2011–2019
Figure 10: Pulmonary Embolism Therapeutics Market, Italy, Revenue ($m), 2006–2011
Figure 11: Pulmonary Embolism Therapeutics Market, Italy, Market Forecast ($m), 2011–2019
Figure 12: Pulmonary Embolism Therapeutics Market, Spain, Revenue ($m), 2006–2011
Figure 13: Pulmonary Embolism Therapeutics Market, Spain, Market Forecast ($m), 2011–2019
Figure 14: Pulmonary Embolism Therapeutics Market, The UK, Revenue ($m), 2006–2011
Figure 15: Pulmonary Embolism Therapeutics Market, The UK, Market Forecast ($m), 2011–2019
Figure 16: Pulmonary Embolism Therapeutics Market, Japan, Revenue ($m), 2006–2011
Figure 17: Pulmonary Embolism Therapeutics Market, Japan, Market Forecast ($m), 2011–2019
Figure 18: Opportunity and Unmet Need in the PE Therapeutics Market
Figure 19: Strategic Competitor Assessment of the Marketed Products for Pulmonary Embolism, 2011
Figure 20: Pulmonary Embolism Therapeutics Market – Clinical Pipeline by Mechanism of Action, 2011
Figure 21: Technology Trends Analytic Framework of the Pulmonary Embolism Pipeline, 2011
Figure 22:Technology Trends Analytic Framework of the Pulmonary Embolism Pipeline – Description, 2011
Figure 23: Pulmonary Embolism Pipeline by Phase of Clinical Development, 2011
Figure 24: Pulmonary Embolism Market, Global, Clinical Trials by Country, 2011
Figure 25: Pulmonary Embolism Therapeutics Market, Global, Clinical Trials by Phase, 2011
Figure 26: Pulmonary Embolism Therapeutics Market, Global, Clinical Trials by Stage of Development, 2011
Figure 27: Pulmonary Embolism Therapeutics Market, Global, Prominent Sponsors, 2011
Figure 28: Pulmonary Embolism Therapeutics Market, Global, Overall Sponsors, 2011
Figure 29: Pulmonary Embolism Therapeutics Market, Global, Companies by Phase, 2011
Figure 30: Pulmonary Embolism Therapeutics Market, Drivers and Restraints, 2011
Figure 31: Implications for Future Market Competition in the Pulmonary Embolism Therapeutics Market, 2011
Figure 32: Pulmonary Embolism Therapeutics Market – Clinical Pipeline by Company, 2011
Figure 33: GlobalData Market Forecasting Model

New Pulmonary Embolism Treatments Offer Patients Freedom from Needles

Treatment for Pulmonary Embolisms (PE) will evolve to better suit patient needs and enhance quality of life, according to a new report by pharmaceutical experts GlobalData.

A new report*upcoming drugs will offer greater convenience and decreased risk of haemeorrahaging, showing a positive future for PE patients. This, along with an increasing global incidence rate and strong therapeutic pipeline, will also lead to the growth of the PE drugs market over the coming years, creating fierce competition amongst market players.

The current primary treatment for PE is anticoagulant therapy, which relies upon long-term oral therapy with vitamin K antagonists, such as warfarin. Current anticoagulant products are associated with serious side effects, such as increased risk of hemorrhage and thrombocytopenia, leading to an increased risk of bleeding.

This severe risk demands frequent patient monitoring to maintain precise dosage adjustment, requiring regular blood samples to be taken, and some of the products themselves are additionally in an injectable form. This brings a risk of low patient compliance, due to the time consuming nature of treatments, alongside pain and needle phobias often associated with blood tests.

GlobalData analysis found that factors associated with needle phobias create a significant unmet need in the global PE treatment market. New therapies with improved efficacy and safety profiles are therefore highly anticipated. Late-stage pipeline OACs expected to launch in the future will offer significant improvements. Bayer Xarelto (rivaroxaban), Bristol-Myers Squibb/Pfizer's apixaban (Eliquis) and Boehringer Ingelheim's Pradaxa (dabigatran etexilate) allow improved ease of administration, with less dosing and less frequent dose adjustment.

The PE pipeline contains as many as 30 molecules in various stages of development, 67% of which are me-too molecules, promising to provide similar treatment to marketed products alongside improved efficacy and safety profiles. These strong pipeline products will improve physician and patient compliance, and intensify competition in the PE therapeutics market, sustaining strong market growth rate during the future.

GlobalData valued the global PE therapeutics market at $2.5 billion in 2011, forecasting growth at a Compound Annual Growth Rate (CAGR) of 7.6% in the immediate future, reaching $4.5 billion by 2019.

* Pulmonary Embolism (PE) Therapeutics - Pipeline Assessment and Market Forecasts to 2019

The report is an essential source of insight into global pulmonary embolism therapeutics, providing actionable analysis on the key trends affecting the market, including pipeline products. The report also provides insights into the prevalent competitive landscape and key players expected to significantly alter the market positioning of the current market leaders. This report was built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis conducted by GlobalData’s team of industry experts.

Boehringer Ingelheim GmbH
Bristol-Myers Squibb
Daiichi Sankyo
Pfizer Inc.
Sanofi

Customers who bought this item also bought

• Pulmonary Embolism Global Clinical Trials Review, H2, 2011
• Pulmonary Embolism - Pipeline Review, H1 2012
• Global Pulmonary Arterial Hypertension Epidemiology and Patient Flow Analysis - 2012
• Global Pulmonary Hypertension Pipeline Capsule - 2013
• Global Pulmonary Fibrosis Pipeline Capsule - 2013
• Respiratory Disorders Therapeutics Market to 2017 - Novel Pipeline Molecules such as VX-770 and pirfenidone May Offset Negative Effect of Patent Expiries
• Pulmonary Embolism - Pipeline Review, H2 2011
• Global Migraine Therapeutics Market: Market Forecast, Patient Flow, Competitive Landscape, and Pipeline Analysis
• Epidemiology: Major Abdominal Surgery - A Key Risk Factor for Deep Vein Thrombosis and Pulmonary Embolism
• Phenylketonuria Therapeutics - Pipeline Assessment and Market Forecasts to 2019